Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: Curis, Inc. is engaged in the research, development, and commercialization of cancer therapeutics. It focuses on developing cancer drug candidates, including CUDC-907, an oral, small molecule drug candidate that is designed to inhibit histone deacetylase and phosphatidylinositol-3-kinase, or PI3K enzymes; CUDC-427, an oral, small molecule drug candidate, which is designed to promote cancer cell death by antagonizing inhibitor of apoptosis proteins; Erivedge, an orally-administered small molecule Hedgehog pathway inhibitor; and Debio 0932, a small molecule inhibitor of heat shock protein 90. It has collaborations with Genentech, Inc. and F. Hoffmann-La Roche Ltd. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-65.47%||Sales Growth - Q/Q||-16.81%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-37.73%||ROE||-51.38%||ROI||-41.08%|
|Current Ratio||10.54||Quick Ratio||Long Term Debt/Equity||0.23||Debt Ratio||0.11|
|Gross Margin||96.5%||Operating Margin||-412.36%||Net Profit Margin||-440.57%||Dividend Payout Ratio|
|Cash From Financing Activities||64.06 M||Cash From Investing Activities||-40.58 M||Cash From Operating Activities||-7.76 M||Gross Profit||1.57 M|
|Net Profit||-31.85 M||Operating Profit||-31.02 M||Total Assets||119.31 M||Total Current Assets||102.55 M|
|Total Current Liabilities||9.73 M||Total Debt||27.38 M||Total Liabilities||31.69 M||Total Revenue||1.66 M|
|High 52 week||2.83||Low 52 week||0.62||Last close||1.82||Last change||2.82%|
|RSI||22.13||Average true range||0.2||Beta||1.08||Volume||507.06 K|
|Simple moving average 20 days||-20.04%||Simple moving average 50 days||-4.65%||Simple moving average 200 days||20.85%|
|Performance Week||-22.55%||Performance Month||-18.75%||Performance Quart||-0.55%||Performance Half||71.7%|
|Performance Year||13.75%||Performance Year-to-date||163.85%||Volatility daily||8.17%||Volatility weekly||18.26%|
|Volatility monthly||37.42%||Volatility yearly||129.62%||Relative Volume||533.41%||Average Volume||195.51 K|
|New High||New Low|
2019-09-12 08:00:00 | Curis Announces Promotion of Bill Steinkrauss to Chief Financial Officer
2019-08-06 16:01:00 | Curis Reports Second Quarter 2019 Financial Results
2019-07-25 15:49:56 | Could Curis, Inc.'s NASDAQ:CRIS Investor Composition Influence The Stock Price?
2019-07-05 16:01:00 | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635c4
2019-05-14 21:03:39 | Edited Transcript of CRIS earnings conference call or presentation 14-May-19 8:30pm GMT
2019-05-14 16:29:33 | Curis: 1Q Earnings Snapshot
2019-05-14 16:05:00 | Curis Reports First Quarter 2019 Financial Results
2019-05-06 08:00:00 | Curis Completes Mesothelioma Enrollment in CA-170 Study
2019-04-26 15:13:48 | Some Curis NASDAQ:CRIS Shareholders Have Taken A Painful 83% Share Price Drop
2019-04-10 08:00:00 | Curis Regains Compliance with Nasdaq Continued Listing Requirements
2019-04-05 16:30:00 | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635c4
2019-03-27 22:16:54 | Edited Transcript of CRIS earnings conference call or presentation 26-Mar-19 8:30pm GMT
2019-03-26 16:17:25 | Curis: 4Q Earnings Snapshot
2019-03-26 16:00:00 | Curis Reports Fourth Quarter and Year-End 2018 Financial Results
2019-03-25 12:05:51 | What's Driving The Rally In Microcap Biotech Curis?
2019-03-25 11:46:02 | Biotech News: Why Curis Stock Is Soaring Today
2019-03-25 08:30:00 | Curis Sells Portion of Erivedge Royalties to Oberland Capital for up to $135.7 million
2019-03-04 08:00:00 | Curis Announces Presentation at Cowen & Company 39th Annual Healthcare Conference
2019-02-04 07:00:00 | Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference
2019-01-29 09:30:02 | Has Curis CRIS Outpaced Other Medical Stocks This Year?
2019-01-24 07:00:00 | First Mesothelioma Patient Dosed in CA-170 Study
2019-01-10 17:53:38 | First Eagle Slashes Curis Stake at Substantial Loss
2019-01-10 09:30:02 | Is Curis CRIS Outperforming Other Medical Stocks This Year?
2019-01-08 12:58:13 | Top 3 Healthcare Penny Stocks for 2018
2019-01-04 16:00:00 | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635c4
2018-11-30 07:45:00 | Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results
2018-11-20 10:45:00 | Curis to Present at the 60th Annual Meeting of the American Society of Hematology
2018-11-02 10:00:33 | Edited Transcript of CRIS earnings conference call or presentation 1-Nov-18 12:30pm GMT
2018-11-01 10:41:02 | Curis CRIS Reports Q3 Loss, Tops Revenue Estimates
2018-11-01 09:04:11 | Curis: 3Q Earnings Snapshot
2018-11-01 07:00:00 | Curis Reports Third Quarter 2018 Financial Results
2018-10-23 08:45:00 | Investor Expectations to Drive Momentum within Ormat Technologies, The Andersons, Freshpet, Curis, Ultra Clean, and Edge Therapeutics — Discovering Underlying Factors of Influence
2018-10-19 10:39:02 | Curis CRIS Shares March Higher, Can It Continue?
2018-10-10 18:44:00 | Top 3 Healthcare Penny Stocks for 2018
2018-10-05 07:00:00 | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635c4
2018-09-27 11:44:36 | Who Are The Top Investors In Curis Inc NASDAQ:CRIS?
2018-09-26 16:05:00 | Curis to Present at the Cantor Fitzgerald Global Healthcare Conference
2018-09-24 16:22:00 | Curis Announces Leadership Change
2018-08-28 16:14:00 | Curis to Present at the Baird 2018 Global Healthcare Conference
2018-08-02 11:50:03 | Curis CRIS Reports Q2 Loss, Lags Revenue Estimates
2018-08-02 11:11:48 | Edited Transcript of CRIS earnings conference call or presentation 2-Aug-18 12:30pm GMT